 |
|
recombinant modified vaccinia Ankara-5T4 vaccine
A cancer vaccine comprised of a recombinant modified vaccinia Ankara (MVA) viral vector encoding the 5T4 fetal oncoprotein (MVA-h5T4). Vaccination with recombinant modified vaccinia Ankara-5T4 vaccine may stimulate the host immune system to mount a humoral and cytotoxic T lymphocyte (CTL) response against tumor cells expressing 5T4 fetal oncoprotein antigen, resulting in tumor cell lysis. The MVA viral vector, derived from the replication-competent strain Ankara, is a highly attentuated, replication-defective vaccinia strain incapable of virion assembly. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
| Synonyms: | | recombinant MVA-5T4 vaccine
recombinant pox virus encoding 5T4 vaccine
vaccinia-5T4 antigen vaccine | | | | US brand name: | | TroVax | | | | Foreign brand name: | | TroVax | | | | Abbreviation: | | rV-5T4 VAC | | |
| Previous: | recombinant interleukin-4, recombinant interleukin-6, recombinant interleukin-7, recombinant macrophage colony-stimulating factor, recombinant MAGE-3.1 antigen | | Next: | recombinant nematode anticoagulant protein c2, recombinant parathyroid hormone, recombinant platelet factor 4, recombinant soluble human CD4 protein, recombinant thyroid-stimulating hormone |
|
|
